TEBENTAFUSP: Tebentafusp Managed Access Program for Metastatic Uveal Melanoma
Uveal melanoma (UM) is a rare and highly malignant neoplasm affecting the vascular layers of the eye (iris, ciliary body, or choroid). Once patients develop metastases, primarily to the liver, the prognosis is poor with a median survival of less than 12 months. There are no effective treatments for metastatic UM that extend survival, and there is no proven standard of care. Enrollment in clinical trials is the treatment option recommended by the UK [...]
Locations: Norfolk and Norwich University Hospital (PI: Jenny Nobes), The Royal Marsden (LONDON) (PI: Andrew Furness), Belfast City Hospital (PI: Judith Carser), Bristol Haematology and Oncology Centre (PI: Hannah Taylor), Royal Preston Hospital (PI: Kellati Prasad), Poole Hospital (PI: Rachel Plant), Cheltenham General Hospital (PI: David Farrugia), William Harvey Hospital (PI: Rosemeen Parkar), Castle Hill Hospital (PI: Dulani Ranataunge), East and North Hertfordshire NHS Trust (PI: Heather Shaw), Nottingham City Hospital (PI: Ankit Rao), University Hospital Birmingham (PI: Leila Khoja), Musgrove Park Hospital (PI: Clare Barlow), The Beatson West of Scotland Cancer Centre (PI: Yun Yi Tan), The Christie NHS Foundation Trust (PI: Paul Lorigan), Royal Cornwall Hospital (PI: Toby Talbot), The Clatterbridge Cancer Centre - LIVERPOOL (PI: Joseph Sacco), The Freeman Hospital (PI: Ruth Plummer)